Bayesian O
computational O
markers O
of O
relapse O
in O
methamphetamine O
dependence O
Methamphetamine O
use O
disorder O
is O
associated O
with O
a O
high O
likelihood O
of O
relapse O
. O

Identifying O
robust O
predictors O
of O
relapse O
that O
have O
explanatory O
power O
is O
critical O
to O
develop O
secondary O
prevention O
based O
on O
a O
mechanistic O
understanding O
of O
relapse O
. O

Computational O
approaches O
have O
the O
potential O
to O
identify O
such O
predictive O
markers O
of O
psychiatric O
illness O
, O
with O
the O
advantage O
of O
providing O
a O
finer O
mechanistic O
explanation O
of O
the O
cognitive O
processes O
underlying O
psychiatric O
vulnerability O
. O

In O
this O
study O
, O
sixty-two O
recently O
sober O
methamphetamine-dependent O
individuals O
were O
recruited O
from O
a O
28-day O
inpatient O
treatment O
program O
, O
and O
completed O
a O
Stop O
Signal O
Task O
( O
SST O
) O
while O
undergoing O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
. O

These O
individuals O
were O
prospectively O
followed O
for O
1 O
year O
and O
assessed O
for O
relapse O
to O
methamphetamine O
use O
. O

Thirty-three O
percent O
of O
followed O
participants O
reported O
relapse O
. O

We O
found O
that O
neural O
activity O
associated O
with O
two O
types O
of O
Bayesian O
prediction O
error O
, O
i.e O
. O

the O
difference O
between O
actual O
and O
expected O
need O
to O
stop O
on O
a O
given O
trial O
, O
significantly O
differentiated O
those O
individuals O
who O
remained O
abstinent O
and O
those O
who O
relapsed O
. O

Specifically O
, O
relapsed O
individuals O
exhibited O
smaller O
neural O
activations O
to O
such O
Bayesian O
prediction O
errors O
relative O
to O
those O
individuals O
who O
remained O
abstinent O
in O
the O
left O
temporoparietal O
junction O
( O
Cohen O
's O
d O
= O
0.91 O
) O
, O
the O
left O
inferior O
frontal O
gyrus O
( O
Cohen O
's O
d O
= O
0.57 O
) O
, O
and O
left O
anterior O
insula O
( O
Cohen O
's O
d O
= O
0.63 O
) O
. O

In O
contrast O
, O
abstinent O
and O
relapsed O
participants O
did O
not O
differ O
in O
neural O
activation O
to O
non-model O
based O
task O
contrasts O
or O
on O
various O
self-report O
clinical O
measures O
. O

In O
conclusion O
, O
Bayesian O
cognitive O
models O
may O
help O
identify O
predictive O
biomarkers O
of O
relapse O
, O
while O
providing O
a O
computational O
explanation O
of O
belief O
processing O
and O
updating O
deficits O
in O
individuals O
with O
methamphetamine O
use O
disorder O
. O

Highlights O
Methamphetamine-dependent O
individuals O
( O
MDI O
) O
face O
a O
high O
rate O
of O
relapse O
after O
treatment O
. O

Can O
a O
Bayesian O
learning O
modeling O
and O
fMRI O
be O
used O
to O
identify O
markers O
of O
relapse O
? O

MDI O
who O
relapsed O
within O
1 O
year O
have O
smaller O
activation O
to O
Bayesian O
model-based O
prediction O
errors O
. O

Such O
neural O
pattern O
was O
observed O
in O
left O
temporo-parietal O
junction O
, O
IFG O
, O
and O
anterior O
insula O
. O

MDI O
more O
likely O
to O
relapse O
show O
weaker O
tracking O
of O
uncertainty O
and O
updating O
of O
their O
belief O
model O
. O

Methods O
Participants O
The O
study O
protocol O
was O
approved O
by O
the O
UCSD O
Human O
Research O
Protections O
Program O
and O
all O
subjects O
gave O
written O
informed O
consent O
. O

Sixty-two O
( O
21 O
% O
female O
) O
recently O
sober O
methamphetamine-dependent O
individuals O
were O
recruited O
from O
a O
28-day O
inpatient O
Alcohol O
and O
Drug O
Treatment O
Program O
at O
the O
Veterans O
Affairs O
San O
Diego O
Healthcare O
System O
and O
Scripps O
Green O
Hospital O
( O
La O
Jolla O
, O
CA O
; O
cross-sectional O
analysis O
of O
these O
data O
published O
elsewhere O
) O
. O

All O
study O
procedures O
, O
including O
the O
neuroimaging O
session O
examining O
brain O
and O
behavior O
responses O
during O
the O
SST O
, O
occurred O
during O
the O
third O
or O
fourth O
week O
of O
treatment O
for O
all O
participants O
( O
i.e. O
, O
all O
had O
been O
abstinent O
from O
methamphetamine O
or O
any O
other O
drugs O
, O
including O
alcohol O
, O
for O
3–4 O
weeks O
) O
. O

To O
maintain O
sobriety O
during O
the O
program O
, O
participants O
were O
screened O
for O
the O
presence O
of O
drugs O
via O
random O
urine O
toxicology O
or O
whenever O
they O
left O
the O
facility O
, O
and O
were O
terminated O
from O
the O
program O
if O
tested O
positive O
. O

Participants O
also O
performed O
the O
North O
American O
Adult O
Reading O
Test O
as O
a O
measure O
of O
verbal O
intelligence O
, O
and O
completed O
self-report O
measures O
of O
personality O
and O
affective O
measures O
previously O
associated O
with O
stimulant O
addiction O
vulnerability O
, O
including O
the O
Barratt O
Impulsiveness O
Scale O
( O
BIS-11 O
) O
, O
the O
Sensation O
Seeking O
Scale O
( O
SSS-V O
) O
, O
and O
the O
Beck O
Depression O
Inventory O
( O
BDI O
) O
. O

Lifetime O
DSM-IV O
Axis O
I O
and O
II O
diagnoses O
at O
baseline O
were O
assessed O
with O
the O
Semi O
Structured O
Assessment O
for O
the O
Genetics O
of O
Alcoholism O
and O
based O
on O
consensus O
meetings O
with O
the O
supervising O
clinician O
and O
trained O
study O
personnel O
, O
including O
a O
Masters-level O
research O
assistant O
and O
postdoctoral-level O
psychologist O
( O
see O
Supplementary O
Text O
1 O
for O
exclusion O
criteria O
) O
. O

Methamphetamine O
dependence O
, O
and O
not O
DSM-5 O
diagnosis O
of O
methamphetamine O
use O
disorder O
, O
was O
assessed O
because O
DSM-IV O
was O
in O
effect O
at O
the O
start O
of O
the O
study O
. O

Participants O
were O
contacted O
one O
year O
later O
for O
a O
brief O
structured O
phone O
interview O
to O
assess O
for O
any O
use O
of O
methamphetamine O
, O
level O
of O
use O
, O
and O
time O
of O
relapse O
. O

At O
baseline O
, O
we O
also O
assessed O
for O
use O
and O
abuse/dependence O
criteria O
for O
other O
drugs O
( O
i.e. O
, O
sedatives O
, O
hallucinogens O
, O
marijuana O
, O
cocaine O
or O
opiates O
) O
in O
the O
past O
year O
, O
as O
part O
of O
a O
larger O
longitudinal O
study O
, O
which O
also O
followed O
individuals O
with O
other O
primary O
drugs O
of O
abuse O
. O

For O
all O
participants O
in O
this O
study O
, O
methamphetamine O
was O
confirmed O
as O
participants O
' O
drug O
of O
choice O
. O

Relapse O
was O
defined O
as O
use O
of O
methamphetamine O
at O
any O
point O
during O
the O
follow-up O
period O
, O
while O
some O
participants O
may O
have O
additionally O
relapsed O
to O
any O
of O
these O
other O
substances O
( O
not O
assessed O
at O
follow-up O
) O
. O

Based O
on O
interview O
responses O
, O
thirty-nine O
methamphetamine-dependent O
individuals O
remained O
abstinent O
from O
methamphetamine O
from O
the O
time O
of O
treatment O
to O
one-year O
follow-up O
. O

Nineteen O
individuals O
reported O
that O
they O
relapsed O
. O

Four O
participants O
could O
not O
be O
tracked O
. O

Stop O
signal O
task O
Participants O
completed O
a O
stop-signal O
task O
( O
6 O
blocks O
of O
48 O
trials O
) O
while O
undergoing O
fMRI O
. O

On O
216 O
go O
trials O
( O
75 O
% O
of O
all O
trials O
) O
, O
they O
had O
to O
press O
as O
fast O
as O
possible O
the O
left O
button O
when O
an O
‘ O
X O
' O
appeared O
or O
the O
right O
button O
when O
an O
‘ O
O O
' O
appeared O
. O

On O
72 O
stop O
trials O
( O
25 O
% O
of O
all O
trials O
) O
, O
they O
heard O
a O
tone O
shortly O
after O
onset O
of O
the O
go O
stimulus O
, O
which O
instructed O
them O
not O
to O
press O
either O
button O
. O

Each O
trial O
lasted O
around O
1300 O
ms O
, O
and O
trials O
were O
separated O
by O
a O
200-ms O
inter-stimulus O
intervals O
( O
blank O
screen O
) O
. O

Individuals O
' O
reaction O
time O
( O
time O
from O
stimulus O
onset O
to O
button O
press O
) O
provided O
a O
natural O
jitter O
. O

The O
sequence O
of O
trial O
types O
presented O
was O
pseudo-randomized O
. O

Finally O
, O
prior O
to O
scanning O
, O
participants O
completed O
the O
SST O
outside O
the O
scanner O
to O
determine O
their O
mean O
‘ O
Go O
’ O
reaction O
time O
( O
MRT O
) O
. O

This O
measure O
was O
then O
used O
to O
determine O
the O
stop O
signal O
delay O
( O
SSD O
) O
for O
six O
different O
types O
stop O
trial O
of O
increasing O
difficulty O
, O
providing O
a O
subject-dependent O
jittered O
reference O
function O
. O

Specifically O
, O
stop O
signals O
were O
delivered O
in O
equal O
amounts O
at O
MRT-0 O
ms O
, O
MRT-100 O
ms O
, O
MRT-200 O
ms O
, O
MRT-300 O
ms O
, O
MRT-400 O
ms O
, O
and O
MRT-500 O
ms O
providing O
an O
individually O
customized O
range O
of O
difficulty O
; O
see O
Supplementary O
Text O
2 O
for O
task O
instructions O
) O
. O

Bayesian O
model O
of O
the O
inhibitory O
response O
expectation O
To O
model O
behavior O
, O
we O
used O
a O
Bayes-optimal O
Dynamic O
Belief O
Model O
, O
which O
has O
been O
robustly O
established O
to O
capture O
behavioral O
adjustments O
in O
the O
SST O
in O
both O
healthy O
individuals O
and O
substance O
users O
. O

The O
model O
assumes O
that O
one O
1 O
) O
updates O
the O
prior O
probability O
of O
encountering O
stop O
trials O
, O
P O
( O
stop O
) O
, O
on O
a O
trial-by-trial O
basis O
based O
on O
trial O
history O
, O
and O
2 O
) O
adjusts O
behavior O
as O
a O
function O
of O
P O
( O
stop O
) O
with O
higher O
predicted O
P O
( O
stop O
) O
prompting O
slower O
Go O
RT O
and O
higher O
likelihood O
of O
correctly O
stopping O
on O
a O
stop O
trial O
. O

Mathematically O
, O
on O
each O
trial O
k O
, O
Pk O
( O
stop O
) O
is O
the O
mean O
of O
the O
predictive O
distribution O
p O
( O
rk|sk-1 O
) O
, O
which O
is O
a O
mixture O
of O
the O
previous O
posterior O
distribution O
and O
a O
fixed O
prior O
distribution O
, O
with O
α O
and O
1 O
− O
α O
acting O
as O
the O
mixing O
coefficients O
, O
respectively O
, O
and O
where O
Sk O
= O
( O
s1 O
, O
… O
, O
sk O
) O
is O
1 O
on O
stop O
trials O
and O
0 O
on O
go O
trials O
: O
with O
the O
posterior O
distribution O
being O
updated O
according O
to O
Bayes O
' O
Rule O
: O
In O
this O
study O
, O
model O
parameters O
for O
the O
beta O
distribution O
p0 O
( O
r O
) O
and O
α O
were O
kept O
constant O
across O
all O
participants O
, O
based O
on O
prior O
simulations O
that O
sought O
to O
optimize O
behavioral O
fit O
at O
the O
group O
level O
, O
i.e. O
, O
maximizing O
the O
goodness-of-fit O
of O
the O
linear O
regression O
of O
P O
( O
Stop O
) O
on O
RT O
across O
all O
participants O
( O
see O
Supplementary O
Text O
3 O
) O
. O

A O
fixed O
setting O
of O
p0 O
= O
Beta O
( O
a O
= O
2.5 O
, O
b O
= O
7.5 O
; O
s O
= O
a O
+ O
b O
= O
10 O
; O
mean O
= O
0.25 O
) O
was O
used O
, O
and O
alpha O
was O
fit O
to O
participants O
' O
data O
( O
range O
tested O
: O
0.25–1.0 O
; O
α O
= O
0.5 O
maximized O
overall O
fit O
across O
all O
participants O
; O
see O
Fig O
. O

1A O
for O
P O
( O
stop O
) O
sequence O
) O
. O

Image O
acquisition O
and O
preprocessing O
Using O
a O
fast O
event-related O
fMRI O
design O
, O
six O
T2 O
* O
-weighted O
EPI O
functional O
runs O
were O
collected O
for O
each O
participant O
, O
along O
with O
one O
T1-weighted O
anatomical O
image O
. O

Each O
scanning O
session O
was O
conducted O
on O
a O
3 O
T O
General O
Electric O
scanner O
with O
the O
following O
parameters O
: O
T2 O
* O
-weighted O
EPI O
, O
repetition O
time O
= O
2000 O
ms O
, O
echo O
time O
= O
40 O
ms O
, O
64 O
× O
64 O
matrix O
, O
30 O
4-mm O
axial O
slices O
, O
FOV O
= O
220 O
× O
220 O
mm O
, O
in-plane O
voxel O
size O
= O
3.437 O
, O
and O
flip O
angle O
= O
90o O
. O

Each O
run O
included O
256 O
repetitions O
for O
a O
length O
of O
8 O
min O
and O
32 O
s. O
Functional O
volume O
acquisitions O
were O
time-locked O
to O
task O
onset O
. O

During O
the O
same O
experimental O
session O
, O
we O
collected O
a O
T1-weighted O
image O
( O
MPRAGE O
, O
TR O
= O
11.4 O
ms O
, O
TE O
= O
4.4 O
ms O
, O
flip O
angle O
= O
10 O
degree O
, O
FOV O
= O
256 O
× O
256 O
, O
1 O
mm3 O
voxels O
) O
to O
be O
used O
for O
anatomical O
reference O
. O

All O
structural O
and O
functional O
image O
processing O
and O
analysis O
was O
performed O
with O
the O
Analysis O
of O
Functional O
Neuroimages O
( O
AFNI O
) O
software O
package O
, O
and O
MRI O
x-y O
slices O
were O
reconstructed O
into O
AFNI O
BRIK O
format O
. O

Echoplanar O
images O
underwent O
automatic O
coregistration O
to O
the O
anatomical O
image O
and O
each O
participant O
dataset O
was O
visually O
inspected O
to O
confirm O
successful O
alignment O
. O

Outlier O
voxels O
were O
identified O
in O
the O
aligned O
images O
based O
on O
whether O
a O
given O
time O
point O
greatly O
exceeded O
the O
mean O
number O
of O
voxel O
outliers O
for O
the O
time-series O
. O

Time O
points O
with O
high O
numbers O
of O
outlier O
voxels O
were O
excluded O
from O
subsequent O
analyses O
. O

First-level O
fMRI O
analyses O
In O
a O
first O
general O
linear O
model O
( O
GLM O
) O
, O
Go O
, O
Stop O
Success/SS O
, O
and O
Stop O
Error/SE O
trials O
were O
distinguished O
and O
convolved O
with O
a O
canonical O
hemodynamic O
response O
function O
( O
Go O
Error O
trials O
were O
scarce O
and O
not O
included O
in O
these O
analyses O
) O
. O

Each O
was O
entered O
as O
both O
categorical O
and O
P O
( O
stop O
) O
-modulated O
regressor O
( O
i.e. O
, O
Go O
, O
SS O
, O
SE O
, O
GoxPk O
( O
stop O
) O
, O
SSxPk O
( O
stop O
) O
, O
and O
SExPk O
( O
stop O
) O
) O
. O

To O
more O
specifically O
isolate O
neural O
activity O
related O
to O
belief O
updating O
processes O
vs O
uncertainty O
tracking O
, O
a O
second O
GLM O
was O
created O
with O
two O
types O
of O
trial-wise O
Bayesian O
prediction O
errors O
as O
parametric O
regressors O
, O
representing O
the O
discrepancy O
between O
expected O
likelihood O
of O
having O
to O
stop O
on O
the O
upcoming O
trial O
( O
i.e. O
, O
P O
( O
stop O
) O
) O
and O
actual O
trial O
type O
observed O
( O
i.e. O
, O
Go O
= O
0 O
, O
Stop O
= O
1 O
) O
. O

These O
regressors O
included O
in O
this O
order O
the O
signed O
prediction O
error O
( O
SPE O
= O
outcome-P O
( O
stop O
) O
= O
sk-Pk O
( O
stop O
) O
) O
and O
the O
unsigned O
prediction O
error O
( O
UPE O
= O
|outcome-Pk O
( O
stop O
) O
| O
= O
|sk-Pk O
( O
stop O
) O
| O
; O
see O
Fig O
. O

1A O
, O
bottom O
) O
, O
as O
well O
as O
trial O
error O
( O
0 O
= O
correct O
or O
1 O
= O
error O
) O
to O
control O
for O
performance O
error O
related O
activity O
. O

Each O
of O
these O
regressors O
were O
orthogonalized O
with O
respect O
to O
the O
preceding O
one O
given O
the O
non-trivial O
collinearity O
between O
them O
. O

Both O
GLMs O
included O
the O
following O
regressors O
of O
no-interest O
: O
a O
baseline O
regressor O
( O
inter-trial O
intervals O
) O
, O
three O
linear O
drift O
regressors O
( O
x O
, O
y O
, O
z O
) O
, O
and O
three O
motion O
regressors O
( O
pitch O
, O
yaw O
, O
roll O
) O
, O
and O
Go O
RTs O
( O
residualized O
with O
respect O
to O
P O
( O
stop O
) O
) O
to O
control O
for O
motor O
response O
confounds O
. O

Images O
were O
spatially O
filtered O
( O
Gaussian O
full O
width O
half O
maximum O
4 O
mm O
) O
to O
account O
for O
individual O
anatomical O
differences O
. O

Automated O
Talairach O
transformations O
were O
applied O
to O
anatomical O
images O
and O
functional O
images O
were O
subsequently O
transformed O
into O
Talairach O
space O
. O

Percent O
signal O
change O
( O
% O
SC O
) O
was O
determined O
by O
dividing O
the O
signal O
for O
each O
regressor O
of O
interest O
by O
the O
baseline O
regressor O
. O

Second-level O
analyses O
At O
the O
between-subject O
level O
, O
two O
types O
of O
voxelwise O
mixed-effects O
linear O
models O
( O
LME O
) O
were O
fit O
to O
the O
coefficients O
of O
our O
first-level O
GLM O
. O

In O
the O
first O
LME O
, O
we O
first O
tested O
for O
the O
interaction O
of O
clinical O
status O
( O
abstinent O
vs O
relapsed O
) O
and O
modulation O
of O
P O
( O
Stop O
) O
under O
each O
Go O
vs O
Stop O
trials O
( O
i.e O
, O
GoxP O
( O
stop O
) O
vs O
StopxPk O
( O
stop O
) O
, O
SS O
and O
SE O
were O
averaged O
) O
, O
with O
subject O
treated O
as O
random O
intercept O
effect O
. O

Whole O
brain O
statistical O
maps O
were O
obtained O
for O
the O
group O
main O
effect O
( O
reflecting O
areas O
tracking O
a O
clinical O
status O
group O
difference O
in O
prior O
P O
( O
stop O
) O
value O
irrespective O
of O
trial O
type O
) O
and O
the O
clinical O
status O
X O
P O
( O
stop O
) O
modulated O
trial O
type O
interaction O
. O

In O
order O
to O
assess O
for O
potential O
group O
difference O
in O
the O
modulation O
of O
trial O
accuracy O
( O
i.e. O
, O
successful O
vs O
failed O
inhibition O
) O
by O
P O
( O
stop O
) O
, O
a O
similar O
LME O
approach O
was O
used O
. O

Specifically O
, O
we O
obtained O
statistical O
maps O
for O
the O
main O
effect O
of O
clinical O
status O
( O
reflecting O
potential O
group O
difference O
in O
P O
( O
stop O
) O
activation O
on O
Stop O
trials O
irrespective O
of O
accuracy O
) O
and O
for O
the O
clinical O
status O
X O
P O
( O
stop O
) O
modulated O
trial O
type O
( O
SE O
vs O
SS O
) O
interaction O
. O

To O
correct O
for O
multiple O
comparisons O
, O
we O
used O
a O
cluster O
threshold O
adjustment O
based O
on O
Monte O
Carlo O
simulations O
( O
generated O
with O
AFNI O
's O
3dClustSim O
program O
) O
. O

We O
first O
calculated O
spatial O
autocorrelation O
function O
( O
acf O
) O
parameters O
from O
the O
1st O
glm O
model O
residuals O
, O
using O
the O
3dFHWMx O
function O
( O
which O
does O
not O
assume O
a O
purely O
Gaussian O
acf O
function O
, O
but O
rather O
a O
mixture O
of O
Gaussian O
and O
mono-exponential O
) O
. O

The O
obtained O
parameters O
, O
averaged O
across O
participants O
, O
were O
fed O
to O
the O
3dClustSim O
function O
to O
determine O
FWER O
corrected O
cluster O
size O
. O

Based O
on O
the O
simulations O
, O
a O
minimum O
cluster O
volume O
of O
896 O
μL O
was O
found O
to O
be O
sufficient O
to O
correct O
for O
multiple O
comparisons O
at O
FWER O
= O
p O
< O
.05 O
with O
a O
minimum O
voxelwise O
significant O
threshold O
of O
p O
< O
.005 O
. O

While O
less O
conservative O
than O
using O
a O
p O
< O
.001 O
or O
p O
< O
.002 O
voxelwise O
threshold O
, O
this O
setting O
provides O
a O
balance O
of O
adequate O
correction O
for O
multiple O
comparisons O
while O
ensuring O
a O
substantial O
minimum O
cluster O
size O
. O

We O
also O
note O
that O
this O
threshold O
is O
still O
relatively O
conservative O
in O
light O
of O
previous O
work O
having O
applied O
this O
Bayesian O
computational O
model O
in O
similar O
populations O
and O
experimental O
settings O
, O
which O
would O
provide O
grounds O
for O
a O
more O
focused O
search O
within O
the O
brain O
based O
on O
regions O
of O
interest O
. O

Finally O
, O
within O
the O
regions O
identified O
with O
those O
LMEs O
, O
we O
identified O
those O
that O
were O
consistent O
with O
a O
potential O
group O
difference O
in O
either O
type O
of O
Bayesian O
prediction O
errors O
( O
UPE O
or O
SPE O
) O
, O
using O
our O
second O
GLM O
for O
regions O
of O
interest O
( O
ROI O
) O
analyses O
. O

Moreover O
, O
for O
regions O
consistent O
with O
a O
group O
main O
effect O
or O
group O
X O
trial O
type O
interaction O
, O
we O
specifically O
checked O
for O
convergence O
between O
results O
from O
the O
second O
GLM O
and O
the O
pattern O
of O
activation O
to O
P O
( O
Stop O
) O
as O
function O
of O
trial O
type O
( O
first O
GLM O
) O
. O

Specifically O
, O
regions O
with O
non-zero O
P O
( O
stop O
) O
activations O
of O
opposite O
signs O
or O
with O
the O
same O
signs O
across O
Go O
and O
Stop O
trials O
, O
should O
be O
consistent O
with O
a O
significant O
group O
difference O
in O
UPE O
and O
SPE O
activations O
, O
respectively O
. O

This O
is O
because O
an O
SPE O
is O
equal O
to O
0 O
- O
P O
( O
stop O
) O
= O
− O
P O
( O
stop O
) O
on O
Go O
trials O
, O
and O
SPE O
= O
1 O
– O
P O
( O
stop O
) O
on O
Stop O
trials O
, O
and O
thus O
negatively O
correlated O
with O
P O
( O
stop O
) O
on O
both O
type O
of O
trials O
. O

In O
contrast O
, O
UPE O
is O
equal O
to O
|0 O
- O
P O
( O
stop O
) O
| O
= O
P O
( O
stop O
) O
on O
Go O
trials O
and O
to O
|1 O
- O
P O
( O
stop O
) O
| O
= O
1 O
– O
P O
( O
stop O
) O
on O
Stop O
trials O
, O
and O
thus O
should O
be O
positively O
correlated O
on O
Go O
trials O
but O
negatively O
correlated O
with O
P O
( O
stop O
) O
on O
Stop O
trials O
( O
see O
. O

